Reaction Biology to acquire Vyant Bio subsidiary’s operations in US
Pharmaceutical Technology
NOVEMBER 4, 2022
Reaction will also obtain lab facilities, equipment, staff, cell lines and expertise in toxicology, pharmacology, pathology and bio analytics from vivoPharm. This will further extend Reaction's industry-leading drug discovery service suite for customers in the biopharmaceutical sector.
Let's personalize your content